drugset / Trial / NCT01307878
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
Phase 3
Completed
320 enrolled
Fudan University
Changhai Hospital · collabRuijin Hospital · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the survival benefit of pre-operation chemotherapy of primary tumor tesection (PTR) compared upfront PTR for colorectal cancer (CRC) patients with an asymptomatic resectable primary tumor and synchronous unresectable liver-limited metastases with conversion therapy intent.
Timeline
- Start
- 2012-06
- Primary completion
- 2021-06
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |